AAPS PharmSciTech

, Volume 19, Issue 5, pp 1971–1984 | Cite as

Effects of the Preparation Process on the Properties of Amorphous Solid Dispersions

  • Siyuan HuangEmail author
  • Robert O. WilliamsIII
Review Article Theme: Applications of KinetiSol® for Advanced Amorphous Solid Dispersions
Part of the following topical collections:
  1. Theme: Applications of KinetiSol® for Advanced Amorphous Solid Dispersions


The use of amorphous solid dispersions to improve the bioavailability of active ingredients from the BCS II and IV classifications continues to gain interest in the pharmaceutical industry. Over the last decade, methods for generating amorphous solid dispersions have been well established in commercially available products and in the literature. However, the amorphous solid dispersions manufactured by different technologies differ in many aspects, primarily chemical stability, physical stability, and performance, both in vitro and in vivo. This review analyzes the impact of manufacturing methods on those properties of amorphous solid dispersions. For example, the chemical stability of drugs and polymers can be influenced by differences in the level of thermal exposure during fusion-based and solvent-based processes. The physical stability of amorphous content varies according to the thermal history, particle morphology, and nucleation process of amorphous solid dispersions produced by different methods. The in vitro and in vivo performance of amorphous formulations are also affected by differences in particle morphology and in the molecular interactions caused by the manufacturing method. Additionally, we describe the mechanism of manufacturing methods and the thermodynamic theories that relate to amorphous formulations.


fusion process solvent process chemical stability physical stability bioavailability amorphous solid dispersion poorly water-soluble drugs 


  1. 1.
    Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64, Supplement:4–17. Scholar
  2. 2.
    Keseru GM, Makara GM. The influence of lead discovery strategies on the properties of drug candidates. Nat Rev Drug Discov. 2009;8(3):203–12. PubMedCrossRefGoogle Scholar
  3. 3.
    Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–49. Scholar
  4. 4.
    Hauss DJ. Oral lipid-based formulations. Adv Drug Deliv Rev. 2007;59(7):667–76. Scholar
  5. 5.
    Ku MS, Dulin W. A biopharmaceutical classification-based right-first-time formulation approach to reduce human pharmacokinetic variability and project cycle time from first-in-human to clinical proof-of-concept. Pharm Dev Technol. 2012;17(3):285–302. Scholar
  6. 6.
    Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2011;420(1):1–10. Scholar
  7. 7.
    Takagi T, Ramachandran C, Bermejo M, Yamashita S, Yu LX, Amidon GL. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm. 2006;3(6):631–43. Scholar
  8. 8.
    Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006;11(19–20):905–10. Scholar
  9. 9.
    Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20. Scholar
  10. 10.
    Brough C, Williams RO III. Amorphous solid dispersions and nano-crystal technologies for poorly water-soluble drug delivery. Int J Pharm. 2013;453(1):157–66. Scholar
  11. 11.
    Hughey JR, Huang S, Williams RO. Solid-state techniques for improving solubility. In: Williams Iii RO, Watts AB, Miller DA, editors. Formulating poorly water soluble drugs. Cham: Springer International Publishing; 2016. p. 121–63.CrossRefGoogle Scholar
  12. 12.
    Lee KWY, Porter CJH, Boyd BJ. The effect of administered dose of lipid-based formulations on the in vitro and in vivo performance of cinnarizine as a model poorly water-soluble drug. J Pharm Sci. 2013;102(2):565–78. Scholar
  13. 13.
    Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004;48(3):791–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Zhang T, Huang P, Shi L, Su Y, Zhou L, Zhu X, et al. Self-assembled nanoparticles of amphiphilic twin drug from floxuridine and bendamustine for cancer therapy. Mol Pharm. 2015;12(7):2328–36. Scholar
  15. 15.
    Banik M, Gopi SP, Ganguly S, Desiraju GR. Cocrystal and salt forms of furosemide: solubility and diffusion variations. Cryst Growth Des. 2016;16(9):5418–28. Scholar
  16. 16.
    Childs SL, Kandi P, Lingireddy SR. Formulation of a Danazol Cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm. 2013;10(8):3112–27. Scholar
  17. 17.
    Roberts AD, Zhang H. Poorly water-soluble drug nanoparticles via solvent evaporation in water-soluble porous polymers. Int J Pharm. 2013;447(1–2):241–50. Scholar
  18. 18.
    Noyes AA, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19(12):930–4. Scholar
  19. 19.
    Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm. 2009;380(1):216–22. Scholar
  20. 20.
    Yang W, Johnston KP, Williams RO III. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats. Eur J Pharm Biopharm. 2010;75(1):33–41. Scholar
  21. 21.
    Birtalan E, Hoelig P, Lindley DJ, Sanzgiri YD, Tong P. Melt-extruded solid dispersions containing an apoptosis-inducing agent. US 20120108590; 2012.Google Scholar
  22. 22.
    Baert LEC, Verreck G, Thoné D. Antifungal compositions with improved bioavailability. US 6509038; 2003.Google Scholar
  23. 23.
    Frank KJ, Rosenblatt KM, Westedt U, Hölig P, Rosenberg J, Mägerlein M, et al. Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. Int J Pharm. 2012;437(1–2):288–93. Scholar
  24. 24.
    Kawakami K. Current status of amorphous formulation and other special dosage forms as formulations for early clinical phases. J Pharm Sci. 2009;98(9):2875–85. Scholar
  25. 25.
    Démuth B, Nagy ZK, Balogh A, Vigh T, Marosi G, Verreck G, et al. Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations. Int J Pharm. 2015;486(1):268–86. Scholar
  26. 26.
    Kittel C. Introduction to solid state physics. New York: Wiley; 2005.Google Scholar
  27. 27.
    Bellantone RA. Fundamentals of amorphous systems: thermodynamic aspects. In: Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. Amorphous solid dispersions: theory and practice. New York: Springer; 2014. p. 3–34.Google Scholar
  28. 28.
    Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW. Amorphous solid dispersions: theory and practice. Berlin: Springer; 2014.CrossRefGoogle Scholar
  29. 29.
    Atkins P, Paula J. Atkins’ physical chemistry. New York: WH Freeman and Company; 2006.Google Scholar
  30. 30.
    Orange Book: approved drug products with therapeutic equivalence evaluations. US Food & Drug Administration. 2016.Google Scholar
  31. 31.
    Madsen CM, Boyd B, Rades T, Müllertz A. Supersaturation of zafirlukast in fasted and fed state intestinal media with and without precipitation inhibitors. Eur J Pharm Sci. 2016;91:31–9. Scholar
  32. 32.
    Tawa M, Almarsson O, Remenar J. Pharmaceutical salts of zafirlukast. Google Patents; 2004.Google Scholar
  33. 33.
    Timko RJ, Bradway RJ, Clements A. Pharmaceutical agents. Google Patents; 1999.Google Scholar
  34. 34.
    Curatolo WJ, Niantic C. Solid pharmaceutical dispersions with enhanced bioavailability. EP 0901786 A2; 1999.Google Scholar
  35. 35.
    Raw AS, Furness MS, Gill DS, Adams RC, Holcombe FO Jr, Yu LX. Regulatory considerations of pharmaceutical solid polymorphism in abbreviated new drug applications (ANDAs). Adv Drug Deliv Rev. 2004;56(3):397–414. Scholar
  36. 36.
    Guo Y, Byrn SR, Zografi G. Physical characteristics and chemical degradation of amorphous quinapril hydrochloride. J Pharm Sci. 2000;89(1):128–43.<128::AID-JPS13>3.0.CO;2-Z.PubMedCrossRefGoogle Scholar
  37. 37.
    Taylor LS, Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res. 1997;14(12):1691–8. Scholar
  38. 38.
    Chauhan H, Hui-Gu C, Atef E. Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions. J Pharm Sci. 2013;102(6):1924–35. Scholar
  39. 39.
    Huang S, O’Donnell KP, Keen JM, Rickard MA, McGinity JW, Williams RO. A new extrudable form of hypromellose: AFFINISOL™ HPMC HME. AAPS PharmSciTech. 2016;17(1):106–19. Scholar
  40. 40.
    European Medicines Agency. Public assessment reports. 2016.Google Scholar
  41. 41.
    Vippagunta SR, Wang Z, Hornung S, Krill SL. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior. J Pharm Sci. 2007;96(2):294–304. Scholar
  42. 42.
    Feng T, Pinal R, Carvajal MT. Process induced disorder in crystalline materials: differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci. 2008;97(8):3207–21. Scholar
  43. 43.
    Craig DQM. The mechanisms of drug release from solid dispersions in water-soluble polymers. Int J Pharm. 2002;231(2):131–44. Scholar
  44. 44.
    Sarode AL, Sandhu H, Shah N, Malick W, Zia H. Hot melt extrusion (HME) for amorphous solid dispersions: predictive tools for processing and impact of drug–polymer interactions on supersaturation. Eur J Pharm Sci. 2013;48(3):371–84. Scholar
  45. 45.
    Timko RJ, Lordi NG. Thermal characterization of citric acid solid dispersions with benzoic acid and phenobarbital. J Pharm Sci. 1979;68(5):601–5. Scholar
  46. 46.
    Breitenbach J. Melt extrusion: from process to drug delivery technology. Eur J Pharm Biopharm. 2002;54(2):107–17. Scholar
  47. 47.
    Qian F, Huang J, Hussain MA. Drug–polymer solubility and miscibility: stability consideration and practical challenges in amorphous solid dispersion development. J Pharm Sci. 2010;99(7):2941–7. Scholar
  48. 48.
    Miller DA, Keen JM. KinetiSol®-based amorphous solid dispersions. In: Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. Amorphous solid dispersions: theory and practice. New York: Springer; 2014. p. 567–77.Google Scholar
  49. 49.
    Hughey JR, McGinity JW. Emerging technologies to increase the bioavailability of poorly water-soluble drugs. In: Williams Iii RO, Watts AB, Miller DA, editors. Formulating poorly water soluble drugs. New York: Springer; 2012. p. 569–602.CrossRefGoogle Scholar
  50. 50.
    LaFountaine JS, Jermain SV, Prasad LK, Brough C, Miller DA, Lubda D, et al. Enabling thermal processing of ritonavir–polyvinyl alcohol amorphous solid dispersions by KinetiSol® dispersing. Eur J Pharm Biopharm. 2016;101:72–81. Scholar
  51. 51.
    Paudel A, Worku ZA, Meeus J, Guns S, Van den Mooter G. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. 2013;453(1):253–84. Scholar
  52. 52.
    Chiang P-C, Ran Y, Chou K-J, Cui Y, Sambrone A, Chan C, et al. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech. 2012;13(2):713–22. Scholar
  53. 53.
    Broman E, Khoo C, Taylor LS. A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug. Int J Pharm. 2001;222(1):139–51. Scholar
  54. 54.
    Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan–chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci. 2009;38(3):206–14. Scholar
  55. 55.
    Yang W, Tam J, Miller DA, Zhou J, McConville JT, Johnston KP, et al. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. Int J Pharm. 2008;361(1–2):177–88. Scholar
  56. 56.
    Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm. 2008;355(1–2):141–9. Scholar
  57. 57.
    Won D-H, Kim M-S, Lee S, Park J-S, Hwang S-J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm. 2005;301(1–2):199–208. Scholar
  58. 58.
    Dobry DE, Settell DM, Baumann JM, Ray RJ, Graham LJ, Beyerinck RA. A model-based methodology for spray-drying process development. J Pharm Innov. 2009;4(3):133–42. Scholar
  59. 59.
    Lowinger M, Baumann J, Vodak DT, Moser J. Practical considerations for spray dried formulation and process development. In: Templeton AC, Byrn SR, Haskell RJ, Prisinzano TE, editors. Discovering and developing molecules with optimal drug-like properties. New York: Springer; 2015. p. 383–435.Google Scholar
  60. 60.
    Shah N, Sandhu H, Choi DS, Chokshi H, Iyer R, Malick AW. MBP technology: composition and design considerations. In: Shah N, Sandhu H, Choi DS, Chokshi H, Malick AW, editors. Amorphous solid dispersions: theory and practice. New York: Springer; 2014. p. 323–50.Google Scholar
  61. 61.
    Sertsou G, Butler J, Scott A, Hempenstall J, Rades T. Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. Int J Pharm. 2002;245(1–2):99–108. Scholar
  62. 62.
    Oguchi T, Yonemochi E, Yamamoto K, Nakai Y. Freeze-drying of drug-additive binary systems. II. Relationship between decarboxylation behavior and molecular states of p-aminosalicylic acid. Chemical & Pharmaceutical Bulletin. 1989;37(11):3088–91. Scholar
  63. 63.
    Mujumdar AS. Handbook of industrial drying. Boca Raton: CRC; 2014.CrossRefGoogle Scholar
  64. 64.
    Mizoe T, Ozeki T, Okada H. Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles. AAPS PharmSciTech. 2008;9(3):755–61. Scholar
  65. 65.
    Sunderland T, Kelly JG, Ramtoola Z. Application of a novel 3-fluid nozzle spray drying process for the microencapsulation of therapeutic agents using incompatible drug-polymer solutions. Arch Pharm Res. 2015;38(4):566–73. Scholar
  66. 66.
    Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 1997;86(1):1–12. Scholar
  67. 67.
    Li M, Hasjim J, Xie F, Halley PJ, Gilbert RG. Shear degradation of molecular, crystalline, and granular structures of starch during extrusion. Starch - Stärke. 2014;66(7–8):595–605. Scholar
  68. 68.
    Hengsawas Surasarang S, Keen JM, Huang S, Zhang F, McGinity JW, Williams RO. Hot melt extrusion versus spray drying: hot melt extrusion degrades albendazole. Drug Dev Ind Pharm. 2016:1–15.
  69. 69.
    Huang S, O’Donnell KP, Delpon de Vaux SM, O’Brien J, Stutzman J, Williams III RO. Processing of a thermally labile drug by hot-melt extrusion. Eur J Pharm Sci. 2017;119:56–57.
  70. 70.
    Rao RN, Ramachandra B, Vali RM, Raju SS. LC–MS/MS studies of ritonavir and its forced degradation products. J Pharm Biomed Anal. 2010;53(4):833–42. Scholar
  71. 71.
    Alexy P, Káchová D, Kršiak M, Bakoš D, Šimková B. Poly(vinyl alcohol) stabilisation in thermoplastic processing. Polym Degrad Stab. 2002;78(3):413–21. Scholar
  72. 72.
    De Jaeghere W, De Beer T, Van Bocxlaer J, Remon JP, Vervaet C. Hot-melt extrusion of polyvinyl alcohol for oral immediate release applications. Int J Pharm. 2015;492(1–2):1–9. Scholar
  73. 73.
    Hughey JR, Keen JM, Brough C, Saeger S, McGinity JW. Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol® dispersing. Int J Pharm. 2011;419(1–2):222–30. Scholar
  74. 74.
    Hughey JR, DiNunzio JC, Bennett RC, Brough C, Miller DA, Ma H, et al. Dissolution enhancement of a drug exhibiting thermal and acidic decomposition characteristics by fusion processing: a comparative study of hot melt extrusion and KinetiSol® dispersing. AAPS PharmSciTech. 2010;11(2):760–74. Scholar
  75. 75.
    DiNunzio JC, Brough C, Miller DA, Williams RO III, McGinity JW. Applications of KinetiSol® dispersing for the production of plasticizer free amorphous solid dispersions. Eur J Pharm Sci. 2010;40(3):179–87. Scholar
  76. 76.
    Wegiel LA, Mauer LJ, Edgar KJ, Taylor LS. Crystallization of amorphous solid dispersions of resveratrol during preparation and storage—impact of different polymers. J Pharm Sci. 2013;102(1):171–84. Scholar
  77. 77.
    Ghebremeskel AN, Vemavarapu C, Lodaya M. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer–surfactant combinations using solubility parameters and testing the processability. Int J Pharm. 2007;328(2):119–29. Scholar
  78. 78.
    Hancock BC, Shamblin SL, Zografi G. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm Res. 1995;12(6):799–806. Scholar
  79. 79.
    Shamblin SL, Tang X, Chang L, Hancock BC, Pikal MJ. Characterization of the time scales of molecular motion in pharmaceutically important glasses. J Phys Chem B. 1999;103(20):4113–21. Scholar
  80. 80.
    Surana R, Pyne A, Suryanarayanan R. Effect of aging on the physical properties of amorphous trehalose. Pharm Res. 2004;21(5):867–74. Scholar
  81. 81.
    Surana R, Pyne A, Suryanarayanan R. Effect of preparation method on physical properties of amorphous trehalose. Pharm Res. 2004;21(7):1167–76. Scholar
  82. 82.
    Bhardwaj SP, Suryanarayanan R. Molecular mobility as an effective predictor of the physical stability of amorphous trehalose. Mol Pharm. 2012;9(11):3209–17. Scholar
  83. 83.
    Bhugra C, Rambhatla S, Bakri A, Duddu SP, Miller DP, Pikal MJ, et al. Prediction of the onset of crystallization of amorphous sucrose below the calorimetric glass transition temperature from correlations with mobility. J Pharm Sci. 2007;96(5):1258–69. Scholar
  84. 84.
    Tsukushi I, Yamamuro O, Suga H. Heat capacities and glass transitions of ground amorphous solid and liquid-quenched glass of tri-O-methyl-ß-cyclodextrin. J Non-Cryst Solids. 1994;175(2):187–94. Scholar
  85. 85.
    Yonemochi E, Inoue Y, Buckton G, Moffat A, Oguchi T, Yamamoto K. Differences in crystallization behavior between quenched and ground amorphous ursodeoxycholic acid. Pharm Res. 1999;16(6):835–40. Scholar
  86. 86.
    Kestur US, Ivanesivic I, Alonzo DE, Taylor LS. Influence of particle size on the crystallization kinetics of amorphous felodipine powders. Powder Technol. 2013;236:197–204. Scholar
  87. 87.
    Ho R, Naderi M, Heng JYY, Williams DR, Thielmann F, Bouza P, et al. Effect of milling on particle shape and surface energy heterogeneity of needle-shaped crystals. Pharm Res. 2012;29(10):2806–16. Scholar
  88. 88.
    Powell CT, Xi H, Sun Y, Gunn E, Chen Y, Ediger MD, et al. Fast crystal growth in o-terphenyl glasses: a possible role for fracture and surface mobility. J Phys Chem B. 2015;119(31):10124–30. Scholar
  89. 89.
    Nandiyanto ABD, Okuyama K. Progress in developing spray-drying methods for the production of controlled morphology particles: from the nanometer to submicrometer size ranges. Adv Powder Technol. 2011;22(1):1–19. Scholar
  90. 90.
    Shah N, Iyer RM, Mair H-J, Choi DS, Tian H, Diodone R, et al. Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. J Pharm Sci. 2013;102(3):967–81. Scholar
  91. 91.
    Andrews GP, Abu-Diak O, Kusmanto F, Hornsby P, Hui Z, Jones DS. Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions. J Pharm Pharmacol. 2010;62(11):1580–90. Scholar
  92. 92.
    Mahmah O, Tabbakh R, Kelly A, Paradkar A. A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine. J Pharm Pharmacol. 2014;66(2):275–84. Scholar
  93. 93.
    Agrawal AM, Dudhedia MS, Patel AD, Raikes MS. Characterization and performance assessment of solid dispersions prepared by hot melt extrusion and spray drying process. Int J Pharm. 2013;457(1):71–81. Scholar
  94. 94.
    Newman A, Zografi G. Critical considerations for the qualitative and quantitative determination of process-induced disorder in crystalline solids. J Pharm Sci. 2014;103(9):2595–604. Scholar
  95. 95.
    Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008;97(4):1329–49. Scholar
  96. 96.
    Taylor LS. Physical stability and crystallization inhibition. Pharmaceutical sciences encyclopedia. Hoboken: Wiley; 2010.Google Scholar
  97. 97.
    Schroers J, Masuhr A, Johnson WL, Busch R. Pronounced asymmetry in the crystallization behavior during constant heating and cooling of a bulk metallic glass-forming liquid. Phys Rev B. 1999;60(17):11855–8.CrossRefGoogle Scholar
  98. 98.
    Guns S, Dereymaker A, Kayaert P, Mathot V, Martens JA, Van den Mooter G. Comparison between hot-melt extrusion and spray-drying for manufacturing solid dispersions of the graft copolymer of ethylene glycol and vinylalcohol. Pharm Res. 2011;28(3):673–82. Scholar
  99. 99.
    Tian Y, Caron V, Jones DS, Healy A-M, Andrews GP. Using Flory–Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying. J Pharm Pharmacol. 2014;66(2):256–74. Scholar
  100. 100.
    Haser A, Cao T, Lubach J, Listro T, Acquarelo L, Zhang F. The effect of processing methods on the stability of naproxen amorphous solid dispersions prepared by melt extrusion and spray drying. Eur J Pharm Sci. 2017;102:115–25.
  101. 101.
    Andronis V, Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Cryst Solids. 2000;271(3):236–48. Scholar
  102. 102.
    Zhou D, Zhang GGZ, Law D, Grant DJW, Schmitt EA. Thermodynamics, molecular mobility and crystallization kinetics of amorphous griseofulvin. Mol Pharm. 2008;5(6):927–36. Scholar
  103. 103.
    Paudel A, Van Humbeeck J, Van den Mooter G. Theoretical and experimental investigation on the solid solubility and miscibility of naproxen in poly(vinylpyrrolidone). Mol Pharm. 2010;7(4):1133–48. Scholar
  104. 104.
    Paudel A, Nies E, Van den Mooter G. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films. Mol Pharm. 2012;9(11):3301–17. Scholar
  105. 105.
    Shah N, Sandhu H, Phuapradit W, Pinal R, Iyer R, Albano A, et al. Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs. Int J Pharm. 2012;438(1–2):53–60. Scholar
  106. 106.
    DiNunzio JC, Brough C, Miller DA, Williams RO, McGinity JW. Fusion processing of itraconazole solid dispersions by kinetisol® dispersing: a comparative study to hot melt extrusion. J Pharm Sci. 2010;99(3):1239–53. Scholar
  107. 107.
    Lang B, McGinity JW, Williams RO. Dissolution enhancement of Itraconazole by hot-melt extrusion alone and the combination of hot-melt extrusion and rapid freezing—effect of formulation and processing variables. Mol Pharm. 2014;11(1):186–96. Scholar
  108. 108.
    Qian F, Huang J, Zhu Q, Haddadin R, Gawel J, Garmise R, et al. Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion? Int J Pharm. 2010;395(1–2):232–5. Scholar
  109. 109.
    Newman A, Knipp G, Zografi G. Assessing the performance of amorphous solid dispersions. J Pharm Sci. 2012;101(4):1355–77. Scholar
  110. 110.
    Javeer SD, Patole R, Amin P. Enhanced solubility and dissolution of simvastatin by HPMC-based solid dispersions prepared by hot melt extrusion and spray-drying method. Journal of Pharmaceutical Investigation. 2013;43(6):471–80. Scholar
  111. 111.
    Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm. 2007;336(1):22–34. Scholar
  112. 112.
    Patterson JE, James MB, Forster AH, Rades T. Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers. Drug Dev Ind Pharm. 2008;34(1):95–106. Scholar
  113. 113.
    Lakshman JP, Cao Y, Kowalski J, Serajuddin ATM. Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. Mol Pharm. 2008;5(6):994–1002. Scholar
  114. 114.
    Bennett RC, Brough C, Miller DA, O’Donnell KP, Keen JM, Hughey JR, et al. Preparation of amorphous solid dispersions by rotary evaporation and KinetiSol dispersing: approaches to enhance solubility of a poorly water-soluble gum extract. Drug Dev Ind Pharm. 2015;41(3):382–97. Scholar
  115. 115.
    DiNunzio JC, Brough C, Hughey JR, Miller DA, Williams Iii RO, McGinity JW. Fusion production of solid dispersions containing a heat-sensitive active ingredient by hot melt extrusion and Kinetisol® dispersing. Eur J Pharm Biopharm. 2010;74(2):340–51. Scholar
  116. 116.
    Zelboraf EMA Assessment report WC500124400; 2011.Google Scholar
  117. 117.
    Miller DA, Keen JM, Brough C, Kucera SU, Ellenberger DJ. Improved formulations of vemurafenib and methods of making the same WO 2016073421 A1; 2016.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  1. 1.Division of Pharmaceutics, College of PharmacyThe University of Texas at AustinAustinUSA
  2. 2.Small Molecule Design and Development, Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA

Personalised recommendations